CA2203165A1 - Immunogenes peptidiques synthetiques du domaine d'ancrage de la membrane de l'ige - Google Patents

Immunogenes peptidiques synthetiques du domaine d'ancrage de la membrane de l'ige

Info

Publication number
CA2203165A1
CA2203165A1 CA 2203165 CA2203165A CA2203165A1 CA 2203165 A1 CA2203165 A1 CA 2203165A1 CA 2203165 CA2203165 CA 2203165 CA 2203165 A CA2203165 A CA 2203165A CA 2203165 A1 CA2203165 A1 CA 2203165A1
Authority
CA
Canada
Prior art keywords
peptide
seq
gly
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2203165
Other languages
English (en)
Inventor
Alan M. Walfield
Chang Yi Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Biomedical Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2203165A1 publication Critical patent/CA2203165A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte à un procédé destiné à déclencher la production, chez des animaux en bonne santé, y compris des êtres humains, d'anticorps à titrage élevé spécifiques des sites se trouvant sur le segment extracellulaire du domaine d'ancrage de la chaîne lourde .epsilon. liée à une membrane de l'IgE humaine exprimée dans les cellules, à l'aide d'une composition comprenant un immunogène peptidique synthétique contenant des sites d'ancrage de la membrane extracellulaire, ceci afin de réduire la production des leucocytes B sécrétant l'IgE et celle de l'IgE induite par des allergènes. L'invention se rapporte également à l'utilisation d'immunogènes comme composants clés, conçus de manière optimale, liés à la chaîne .epsilon. de l'IgE, dépourvus de protéines porteuses, dans un vaccin synthétique afin d'assurer une immunothérapie s'appliquant au traitement des allergies. Les peptides de l'invention contiennent des séquences stimulatrices immunes, y compris un épitope des lymphocytes T auxiliaires liés en tandem, afin de faciliter la stimulation de la réponse immune vers le domaine d'ancrage de la membrane de mIgE.
CA 2203165 1994-10-25 1995-10-25 Immunogenes peptidiques synthetiques du domaine d'ancrage de la membrane de l'ige Abandoned CA2203165A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32851994A 1994-10-25 1994-10-25
US08/328,519 1994-10-25

Publications (1)

Publication Number Publication Date
CA2203165A1 true CA2203165A1 (fr) 1996-05-02

Family

ID=23281314

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2203165 Abandoned CA2203165A1 (fr) 1994-10-25 1995-10-25 Immunogenes peptidiques synthetiques du domaine d'ancrage de la membrane de l'ige

Country Status (5)

Country Link
EP (1) EP0787150A1 (fr)
CN (1) CN1167491A (fr)
AU (1) AU4012095A (fr)
CA (1) CA2203165A1 (fr)
WO (1) WO1996012740A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2193413C2 (ru) 1996-03-01 2002-11-27 Новартис Аг Пептидные иммуногены для вакцинации и лечения аллергии
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
EP1497654A4 (fr) 2001-08-13 2006-06-07 Chen Swey Shen Alex Vaccins d'immunoglobuline e et leurs procedes d'utilisation
AU2003243663A1 (en) * 2002-06-20 2004-01-06 The Trustees Of The University Of Pennsylvania Vaccines for suppressing ige-mediated allergic disease and methods for using the same
DE102004035337A1 (de) * 2004-07-21 2006-03-16 Merck Patent Gmbh Varianten der Gruppe 1-Allergene aus Poaceae mit reduzierter Allergenität und erhaltener T-Zellreaktivität
US8137670B2 (en) 2005-09-29 2012-03-20 Medimmune, Llc Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells
WO2007131129A2 (fr) * 2006-05-03 2007-11-15 Guthrie Foundation For Education & Research Déterminants de surface cellulaire associés à l'immunoglobuline dans le traitement de troubles des lymphocytes b
ES2478242T3 (es) 2007-03-22 2014-07-21 Genentech, Inc. Anticuerpos anti IgE apoptóticos que se unen con el IgE unido a membrana
US8491911B2 (en) * 2008-10-15 2013-07-23 Alk-Abello A/S Pharmaceutical product for up-dosing of allergy vaccine
AU2010217100B2 (en) 2009-02-25 2014-03-27 Academia Sinica Anti-CepsilonmX antibodies capable of binding to human mIgE on B lymphocytes
DE102009034779A1 (de) 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
CA2800774A1 (fr) * 2010-06-07 2011-12-15 Pfizer Vaccines Llc Vaccin peptidique ige ch3
CN104603150A (zh) 2012-04-20 2015-05-06 中央研究院 与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体
JP5918851B2 (ja) * 2012-06-18 2016-05-18 日本全薬工業株式会社 ＩｇＥペプチドワクチン
EP3319988A1 (fr) 2015-07-07 2018-05-16 Affiris AG Vaccins pour le traitement et la prévention de maladies médiées par ige
EP3703753A4 (fr) 2017-10-31 2021-08-18 Oneness Biotech Co., Ltd. Traitement de maladies allergiques médiées par ige
WO2019133024A1 (fr) * 2017-12-31 2019-07-04 United Biomedical, Inc. Immunogènes peptidiques et formulations de ceux-ci ciblant les ige membranaires pour le traitement de maladies allergiques médiées par les ige

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5342924A (en) * 1987-12-31 1994-08-30 Tanox Biosystems, Inc. Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor
US5260416A (en) * 1987-12-31 1993-11-09 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted IgE
US5274075A (en) * 1987-12-31 1993-12-28 Tanox Biosystems, Inc. Newly identified human epsilon immunoglobulin peptides and related products
US5231026A (en) * 1987-12-31 1993-07-27 Tanox Biosystems, Inc. DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE
US5281699A (en) * 1990-06-01 1994-01-25 Tanox Biosystems, Inc. Treating B cell lymphoma or leukemia by targeting specific epitopes on B cell bound immunoglobulins

Also Published As

Publication number Publication date
EP0787150A1 (fr) 1997-08-06
WO1996012740A1 (fr) 1996-05-02
AU4012095A (en) 1996-05-15
CN1167491A (zh) 1997-12-10

Similar Documents

Publication Publication Date Title
US7648701B2 (en) Peptide composition as immunogen for the treatment of allergy
CA2329772C (fr) Epitopes de lymphocytes t auxiliaires artificiels tenant lieu d'immunostimulateurs pour constituer des immunogenes peptidiques de synthese
CA2203165A1 (fr) Immunogenes peptidiques synthetiques du domaine d'ancrage de la membrane de l'ige
WO1995026365A1 (fr) Immunogenes a base de peptide synthetique pour le traitement de l'allergie
CA2161445C (fr) Peptides de lhrh immunogenes et stimulateurs universels synthetiques de l'immunite pour les vaccins
MXPA00011298A (es) Epitopes artificiales de celulas asistentes t como inmunoestimuladores para inmunogenos peptidicos sinteticos que incluyen peptidos lhrh inmunogenicos.
US6780969B2 (en) Synthetic peptide composition as immunogens for prevention of urinary tract infection
US20030152581A1 (en) Compound and method for the prevention and/or the treatment of allergy
IE911527A1 (en) Improved vaccine compositions
JPH02502637A (ja) 合成抗むしばワクチン
IE911614A1 (en) Epitopes of the pre-s region of hepatitis b virus surface¹antigen
MXPA00011938A (en) Peptide composition as immunogen for the treatment of allergy
MXPA00011939A (en) Artificial t helper cell epitopes as immune stimulators for synthetic peptideimmunogens
MXPA00011752A (en) Synthetic somatostatin immunogen for growth promotion in farm animals

Legal Events

Date Code Title Description
FZDE Dead